Rhenman & Partners Asset Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Rhenman & Partners Asset Management’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-267	Closed	-$2.27M	–	101
2015 Q1	$2.27M	Sell	267 -169	-39%	-$1.48M	0.38%	82
2014 Q4	$3.83M	Sell	436 -134	-24%	-$778K	1.11%	30
2014 Q3	$2.68M	Buy	570 +468	+459%	+$2.47M	0.79%	47
2014 Q2	$737K	Buy	+102	New	+$510K	0.22%	90

Other funds holding EIGR

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Rhenman & Partners Asset Management's EIGR Position: Q2 2015 in Review

Rhenman & Partners Asset Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2015, closing a stake of 267 shares — an estimated $2.27M sold.

Rhenman & Partners Asset Management first reported a position in EIGR in Q2 2014 and held it in 4 quarters. The position peaked at $3.83M in Q4 2014. 44 funds tracked by Wall St. Rank hold EIGR as of Q2 2015.

Rhenman & Partners Asset Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
Rhenman & Partners Asset Management sold 267 Eiger BioPharmaceuticals, Inc. shares in Q2 2015, an estimated $2.27M.
Rhenman & Partners Asset Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2014 and held it in 4 quarters.
Rhenman & Partners Asset Management's Eiger BioPharmaceuticals, Inc. position peaked at $3.83M in Q4 2014.
44 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2015.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2015, filed 30 Jul 2015.